The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC).
 
Samuel Black
No Relationships to Disclose
 
Kai Yu
No Relationships to Disclose
 
Mohammad Jad Moussa
No Relationships to Disclose
 
Cindy Jiang
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; GT Aperion; Guardant Health; Harbinger Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Matthew Campbell
Honoraria - Curio Science; Eisai; Exelixis; MJH Life Sciences; OnViv; Seagen; Targeted Oncology
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - Exelixis; SeaGen
 
Linghua Wang
No Relationships to Disclose
 
Jianping Zhao
No Relationships to Disclose
 
Charles Guo
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)